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Abstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the 
only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinase 
inhibitors represent a newer generation of chemotherapeutic agents targeting speciﬁ  c tumor 
pathways associated with carcinogenesis including cell cycle control, signal transduction, 
apoptosis and angiogenesis. These agents present a more selective way of treating pancreatic 
cancer. Erlotinib is the prototype of the tyrosine kinase inhibitors with proven efﬁ  cacy in 
advanced pancreatic cancer and has been recently approved in that setting. Multiple other 
tyrosine kinase inhibitors targeting the VEGFR, PDGFR, and Src kinases are in various 
phases of clinical trials testing. The preliminary results of these trials have been disappointing. 
Current challenges in pancreatic cancer clinical trials testing include improving patient 
selection, identifying effective combinations, improving the predictive value of current 
preclinical models and better study designs. This review summarizes the present clinical 
development of tyrosine kinase inhibitors in pancreatic cancer and strategies for future drug 
development.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer deaths in the US with 
more than 30,000 deaths annually (Jemal et al 2007). More than 75% of patients 
with pancreatic cancer present with locally advanced or metastatic disease (El-Rayes 
and Philip 2003). Median survival remains poor and is estimated to be about 6 months 
for people with metastatic disease (Bramhall et al 1995). Pancreatic cancer is resistant 
to both conventional chemotherapy and radiation (Brand and Tempero 1998).
Gemcitabine is the only cytotoxic drug approved for advanced pancreatic cancer 
in the ﬁ  rst-line setting (Burris et al 1997). In a pivotal phase III trial, gemcitabine 
was compared to ﬂ  uorouracil (5-FU) in previously untreated pancreatic carcinoma. 
Gemcitabine resulted in a signiﬁ  cant improvement in the clinical beneﬁ  t score (pain 
control, weight gain and performance status) over 5-FU. The objective response to 
gemcitabine was less than 10%. An improvement in median survival from 4.2 to 
5.7 months was observed. The overall survival at 1 year improved from 2% to 18%. 
Gemcitabine has become the standard of care (Regine and Abrams 2006; Oettle et al 
2007) for advanced pancreatic cancer. Combination chemotherapy regimens based on 
the gemcitabine platform have failed to show any signiﬁ  cant survival advantage over 
single agent gemcitabine (Rocha Lima et al 2004; Louvet et al 2005).
The development of agents targeting speciﬁ  c tumor pathways including tyrosine 
kinases has been viewed as a promising approach for the treatment of pancreatic 
cancer. The initial results of clinical trials of tyrosine kinase inhibitors in pancreatic 
cancer have however been disappointing.Biologics: Targets & Therapy 2008:2(4) 708
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Tyrosine kinases in cancer
Cytoplasmic TKs and receptor TKs
Tyrosine kinases are a major subclass of protein kinases 
that play a pivotal role in intracellular signal transduction 
(Kleespies et al 2006). Tyrosine kinases can be either 
receptor tyrosine kinases (RTK) or non-receptor cytoplas-
mic tyrosine kinases (Levitzki and Gazit 1995; Levitzki 
1999). All RTKs contain an extracellular ligand binding 
domain that is connected to the cytoplasmic catalytic 
domain by a transmembrane helix. RTKs are activated by 
various growth factor ligands such as epidermal growth 
factor (EGF), vascular endothelial growth factor (Lev-
itzki 1999; Schlessinger 2000). Ligand binding induces 
dimerization of the cell-surface receptors resulting in auto-
phosphorylation of the cytoplasmic domains and activation 
of the receptor’s tyrosine kinase (Olayioye et al 2000; 
Schlessinger 2000). Speciﬁ  cally, RTKs catalyze transfer of 
phosphates from ATP to the hydroxyl groups of tyrosines on 
target proteins. Phosphorylated tyrosines serve as binding 
sites for a number of cytoplasmic signal-transducing mol-
ecules, activating downstream signalling pathways (Sch-
lessinger 2000; Yarden and Sliwkowski 2001). Downstream 
signalling occurs mainly via the Ras/Raf/MAP kinase 
pathway, the phosphatidyl-inositol phosphate kinase (PIP 
Kinase/PI-3K)/AKT pathway, and the JAK/STAT nuclear 
translocation. Activation or inhibition of these pathways 
modulates cell cycle processes like migration, metabolism, 
apoptosis and survival and differentiation. RTK function 
can be dysregulated by multiple mechanisms including 
oncogene mutations leading to constitutive activation of 
the kinase, ampliﬁ  cation of the RTK gene, over-production 
of growth factors ligands or abnormalities in the inhibitory 
pathways.
Cytoplasmic tyrosine kinases on the other hand do 
not have an extracellular receptor and are located in the 
cytoplasm, nucleus or plasma membrane. They consist of 
eight families with the major ones including SRC, JAK, 
ABL, FAK (Levitzki 1999).
EGFR targeting 
in pancreatic cancer
The Erb family consists of four related receptors: the EGFR 
(EGFR/HER-1/ErbB-1), ErbB-2 (HER-2/neu), ErbB-3 
(HER3) and ErbB-4 (HER-4) (Olayioye et al 2000; Arteaga 
2001; Yarden and Sliwkowski 2001). Enhanced signaling 
from these receptors due to mutation or over-expression 
contributes to several types of human cancers including 
lung, breast, colorectal, brain, head and neck, ovarian 
and pancreatic (Yarden and Sliwkowski 2001; Hubbard 
2006). Elevated expression of the EGFR or its ligand is 
also associated with worse clinical outcomes in a variety 
of epithelial cancers including colorectal, pancreatic, 
head and neck, and breast cancer (Yamanaka et al 1993; 
Dong et al 1998; Papageorgio and Perry 2007). ErbB-1 
receptor expression is detected in upto 90% of pancreatic 
tumors (Lemoine, Hughes et al 1992). Over-expression of 
EGFR signalling is believed to induce increased survival, 
proliferation, chemoresistance and invasiveness of pancreatic 
tumors (Yamanaka et al 1993).
EGFR can be targeted therapeutically by monoclonal 
antibodies or small molecule tyrosine kinase inhibitors 
(TKI). Monoclonal antibodies interact with the extracellular 
domain of EGFR, inhibiting EGF ligand binding and inducing 
receptor endocytosis. Occasionally the Fc portion of some 
monoclonal antibodies may induce antibody-dependent cellular 
cytotoxicity (ADCC), mediating tumor cell lysis. The small 
molecule TKIs act intracelullarly by interfering with the ATP 
binding site of the EGFR tyrosine kinase thereby inhibiting its 
trans-phosphorylation of tyrosine residues on target proteins 
(Ritter and Arteaga 2003). In-vitro both the monoclonal anti-
bodies and the small molecule TKIs efﬁ  ciently block the EGFR 
signal transduction pathways inducing tumor cell cycle arrest, 
potentiating apoptosis, inhibiting angiogenesis, inhibiting tumor 
invasion and metastasis and augmenting chemo-radiotherapy 
anti-tumor effects (Mendelsohn and Baselga 2006).
Erlotinib
Erlotinib (Tarceva®, OSI-774) is a reversible oral ErbB-1 
tyrosine kinase inhibitor approved in pancreatic cancer. 
Five hundred sixty-nine patients with locally advanced or 
metastatic pancreatic cancer were randomized to receive 
gemcitabine plus placebo or gemcitabine and erlotinib 
100 mg a day (Moore, Goldstein et al 2007). Primary 
endpoint was overall survival with secondary endpoints being 
progression-free survival, response rate and improvement in 
the quality of life. The erlotinib plus gemcitabine arm had 
a higher median survival of 6.2 months versus 5.9 months 
with a hazard ratio of 0.82 (95% CI; 0.6 7–0.97, p = 0.034). 
One-year survival was 23% in the erlotinib plus gemcitabine 
arm versus 17% in the gemcitabine alone arm. In multivariate 
analysis signiﬁ  cant predictors of survival were treatment 
with erlotinib, good performance status, locally advanced 
disease and normal serum albumin. The progression-free 
survival was also favorable in the erlotinib arm (3.75 months 
versus 3.55 months) with a hazard ratio of 0.76 (p = 0.03). 
Although there was a higher incidence of grade 1 and 2 rash Biologics: Targets & Therapy 2008:2(4) 709
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and diarrhea in the erlotinib arm, there were no signiﬁ  cant 
differences in grade 3 and 4 toxicities. No correlation could be 
found between EGFR expression by immunohistochemistry 
and clinical beneﬁ  t from erlotinib. Based on this modest 
beneﬁ  t, erlotinib was approved for use in combination with 
gemcitabine in patients with pancreatic cancer who have 
received no prior therapy.
Single agent erlotinib in advanced pancreatic cancer
Erlotinib as a single agent was evaluated in patients with 
pancreatic cancer who had failed prior chemotherapy 
(Epelbaum et al 2007). The primary end-point for evaluation 
was progression-free survival. Thirteen patients were treated 
with single agent erlotinib with median treatment duration 
being 2 months. Median time to tumor progression was 
1 month. Five patients (38%) showed clinical improvement 
or disease stabilization with decrease in tumor markers. Thus 
erlotinib seems to have activity as a single agent in pancreatic 
cancer but needs to be investigated further in this setting.
Geﬁ  tinib
Geﬁ  tinib (Iressa®, ZD1839) is an oral small molecule TKI 
speciﬁ  cally targeting ErbB-1 receptor. Geﬁ  tinib completely 
abolished EGF-induced phosphorylation of EGFR/MAP 
Table 1 Ongoing clinical trials evaluating tyrosine kinase inhibitors in pancreatic cancer
Drug Class Phase Concurrent therapy
1. Erb inhibitors
 erlotinib EGFR II RAD001  (everolimus)
 erlotinib EGFR II bevacizumab,  gemcitabine
 erlotinib EGFR II gemcitabine,  oxalipaltin
 erlotinib EGFR III capecitabine,  gemcitabine
  erlotinib EGFR III gemcitabine, capecitabine, radiation
  erlotinib EGFR I/II bevacizumab, gemcitabine, capecitabine
 erlotinib EGFR I/II cetuximab
 erlotinib EGFR I/II gemcitabine
  erlotinib EGFR II gemcitabine, capecitabine, radiation
 erlotinib EGFR II bevacizumab
 erlotinib EGFR II gemcitabine,  panitumumab
 lapatinib Pan  Erb II gemcitabine
2. Combined Erb/VEGFR inhibitors
 BMS-690514 Pan  Erb/VEGFR I –
  vandetanib (ZD6474) EGFR/VEGFR I gemcitabine, capecitabine
3.   VEGFR inhibitors
 sunitinib VEGFR III –
 sunitinib VEGFR I gemcitabine
 PTK787/ZK222584 VEGFR II –
 PTK787/ZK222584 VEGFR I/II gemcitabine
 axitinib  (AG-013736) VEGFR III gemcitabine
 brivanib  (BMS-582664) VEGFR/FGFR II –
4. Combined VEGFR/PDGFR inhibitors
 sorafenib VEGFR/PDGFR III gemcitabine
 sorafenib VEGFR/PDGFR I/II oxalipaltin,  capecitabine
 sorafenib VEGFR/PDGFR I sirolimus
5. PDGFR inhibitors
 Imatinib PDGFR II Gemcitabine
6. Src kinase inhibitors
 Dasatinib Src  kinase II –
  Dasatinib Src kinase I/II Gemcitabine, Cetuximab
 AZD0530 Src  kinase I/II GemcitabineBiologics: Targets & Therapy 2008:2(4) 710
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kinase and inhibited EGF-induced cell growth and invasion 
in pancreatic cancer cell lines (Li et al 2004). Efficacy 
of gefitinib in combination with docetaxel was tested in 
a phase II study of metastatic pancreatic cancer patients who had 
failed prior gemcitabine-based chemotherapy (Blaszkowsky 
et al 2007). Primary endpoint of the study was CA19-9 
response (50% decrease in tumor marker CA19-9 levels) with 
additional endpoints including radiologic response, toxicity, 
and survival. Fifteen patients were treated with geﬁ  tinib and 
docetaxel with good tolerance and minimal toxicities. No 
patient experienced a biochemical (CA19-9) response to 
treatment, although 9 out of 15 evaluable patients experienced 
stable disease. The combination was reported to be inactive in 
metastatic pancreatic cancer and the trial was stopped due to 
lack of efﬁ  cacy.
Lapatinib
Lapatinib is a small molecule TKI that reversibly inhibits 
ErbB-1 and ErbB-2. Lapatinib had shown activity against 
pancreatic tumor cell lines and was tested in a phase 1 
trial in advanced pancreaticobiliary cancer (Safran et al 
2006). A two-stage trial using lapatinib with gemcitabine 
and gemcitabine/oxalipaltin combination was conducted 
enrolling 21 patients, 15 with pancreatic cancer and 5 with 
biliary cancer. Five of the 20 evaluable patients showed 
partial responses with dramatic responses seen in patients 
with diffuse liver and peritoneal metastases. The results of 
the trial demonstrated that lapatinib can be safely combined 
with gemcitabine based chemotherapy. The preliminary 
efﬁ  cacy results were encouraging.
Future strategies targeting EGFR 
pathways
Although there was a statistically signiﬁ  cant improvement 
in overall and median survival with the addition of erlotinib, 
most physicians agree that the improvement is at best modest. 
The negative result of the phase III trial with cetuximab 
(Philip et al 2007) confirms that targeting the EGFR 
pathway in pancreatic cancer has limited beneﬁ  t. Newer 
approaches being evaluated in clinical trials in pancreatic 
cancer include:
1.  Use of agents that target multiple members of the Erb family 
like lapatinib. The rationale is that hetero-dimerization of 
EGFR with other members of the Erb family may contribute 
to the resistance against selective EGFR inhibitors. 
Therefore, targeting multiple members of the Erb family 
may be necessary to block the growth/survival signal from 
the EGFR pathway.
2.  Combining erlotinib with other biologic agents. Since the 
signalling pathway in pancreatic cancer is dysregulated 
at multiple levels, inhibition of only the RTK may 
be insufficient to alter the chemoresistant nature of 
pancreatic cancer. Erlotinib was studied in combination 
with antiangiogenic agents such as bevacizumab 
in advanced pancreatic cancer. In a phase III trial, 
607 chemonaive patients with metastatic pancreatic 
adenocarcinoma were randomized to gemcitabine and 
erlotinib or gemcitabine, erlotinib and bevacizumab 
(Vervenne et al 2008). The primary endpoint was 
overall survival. Median overall survival was 6 months 
in the gemcitabine/erlotinib arm versus 7.1 months in 
the gemcitabine/erlotinib/bevacizumab arm (HR 0.89; 
95% CI 0.74–1.07). Median progression free survival was 
3.6 months in gemcitabine/erlotinib arm versus 4.6 months 
in the combination arm (HR 0.73; 95% CI 0.61–0.86; 
p = 0.0002). No clinically relevant differences were 
observed in clinical response and Grade 3–4 adverse 
events between the two arms. At our institution, we are 
evaluating the combination of erlotinib with inhibitors of 
the Akt/ NF-kB.
3.  Combining EGFR blockade with non-gemcitabine based 
cytotoxic agents such as docetaxel or ixabepilone.
4.  Combining erlotinib with radiation. Erlotinib has 
been analyzed in a phase I study in combination with 
chemoradiation followed by maintenance erlotinib for 
locally advanced pancreatic cancer (Iannitti et al 2005).
VEGF targeting 
in pancreatic cancer
Tumor progression and metastasis is critically dependent 
upon angiogenesis (Folkman 1971; Hicklin and Ellis 2005). 
Angiogenesis depends on the balance of several pro and anti 
angiogenic factors. Various tumor cells including pancreatic 
cancer commonly secrete a potent pro-angiogenic factor, 
the vascular endothelial growth factor (VEGF). VEGF-A 
increases microvascular permeability, stimulates endothelial 
cell migration, proliferation and protects them from apoptosis 
(Ferrara 1999; Dvorak 2002). VEGF – A mediates its effects 
by interacting with its two high afﬁ  nity vascular endothelial 
growth factor receptors (VEGFR): VEGFR-1 (Flt-1) and 
VEGFR-2 (KDR/Flk-1). VEGR-1 and VEGFR-2 are high 
afﬁ  nity transmembrane tyrosine kinase receptors selectively 
expressed by normal vascular and over-expressed in tumor 
endothelium (Dvorak 2002). VEGFR-3 (Flt-4) is another 
VEGFR that binds to other members of the VEGF ligand 
family, VEGF-C and VEGF-D. VEGFR-3 is normally Biologics: Targets & Therapy 2008:2(4) 711
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expressed in the lymphatic endothelium and is also 
over-expressed in tumor cells. Similar to the EGFR signalling 
pathways, VEGF ligands on binding to their VEGF receptors 
initiate phosphorylation of the receptor tyrosine kinases. This 
sets off a cascade of downstream signalling events resulting 
in the activation of phospholipase Cγ, PI-3K and Ras/MAP 
Kinase, mediating endothelial and lymphatic cell migration 
and proliferation (Dvorak 2002).
Oncogene/tumor suppressor gene activation, tissue 
hypoxia and cytokine secretion by pancreatic cancer cells 
results in increased expression of VEGF and VEGFR 
(Cherrington et al 2000; Baker et al 2001; Dvorak 2002). 
Higher serum and intra-tumoral expression levels of VEGF 
have been associated with larger tumor size, enhanced 
local progression (Itakura et al 2000), earlier recurrence 
after surgical resection (Niedergethmann et al 2002) and 
an overall worse prognosis in pancreatic cancer (Ikeda et al 
1999; Luo et al 2001; Buchler et al 2002). Inhibition of the 
VEGF pathway has also been shown to make pancreatic cell 
line more sensitive to the cytotoxic effects of conventional 
chemotherapy like gemcitabine (Bruns et al 2002). VEGF 
signaling pathways have been targeted for treatment by the 
use of anti-VEGF monoclonal antibodies, antibodies binding 
to VEGFR and VEGFR tyrosine kinase inhibitors.
Vatalanib (PTK787/ZK222584)
Vatalanib is a pan-VEGFR tyrosine kinase inhibitor with 
activity against VEGFR-1, VEGFR-2 and VEGFR-3. 
Vatalanib also has activity against platelet derived growth 
factor receptor (PDGFR) and c-kit (Wood et al 2000). After 
demonstrating activity in preclinical studies and orthotopic 
pancreatic cancer models, vatalanib has been tested in 
phase I settings, the preliminary results of which were 
recently reported (Kuo T. 2006). In this study advanced 
pancreatic cancer patients are being treated with vatalanib and 
gemcitabine. Eleven patients have been enrolled so far, with 
2 patients (18%) showing a partial response and 6 patients 
(55%) with stable disease. The combination of gemcitabine 
and vatalanib is well-tolerated with some antitumor responses 
observed and accrual is continuing.
Vandetanib
Vandetanib (ZD-6474) is a TK inhibitor of VEGFRR-2, 
VEGFR-3, Ret and EGFR (Ciardiello et al 2003) thus 
inhibiting both the VEGF dependent angiogenesis and EGFR 
dependent tumor cell proliferation. Vandetanib has shown 
signiﬁ  cant activity in preclinical models with enhanced 
synergism with gemcitabine (Bruns 2003; Conrad et al 2007) 
prompting it to be tested in clinical settings. Vandetanib is 
being studied in combination with gemcitabine in patients 
with pancreatic cancer.
Axitinib (AG013736)
Axitinib (AG-013736) is a small molecule TKI with potency 
against pan VEGF receptors and against PDGFR-β and 
c-Kit (Spano JP 2006). Axitinib in preclinical studied has 
been shown to be a very effective anti-angiogenesis agent 
(Inai et al 2004). A phase I study in solid tumors identiﬁ  ed 
5 mg twice a day as the therapeutic dose (Rugo et al 2005). 
AG-013736 was subsequently studied in combination with 
gemcitabine as ﬁ  rst-line therapy for advanced pancreatic 
cancer in a phase II trial (Spano et al 2008). One hundred 
and eight patients were randomized in a 2:1 ratio to receive 
gemcitabine and axitinib (n = 69) or gemcitabine alone 
(n = 34). Primary endpoint was overall survival. Median 
overall survival was 6.9 months (95% CI 5.3–10.1) in the 
combination arm versus 5.6 months (95% CI 3.9–8.8) in 
the gemcitabine alone arm. Except for grade 3 fatigue, 
the safety proﬁ  le was similar. Based on the results of this 
study gemcitabine and axitinib will be evaluated further in 
a phase III trial.
PDGFR targeting 
in pancreatic cancer
Platelet-derived growth factor ligands, PDGF-A and 
PDGF-B, exert their effects on target cells by activating the 
two structurally related protein tyrosine kinase receptors, 
PDGFR-α and PDGFR-β. Activation of PDGFR leads to 
downstream signal transduction via PI-3K, Phospholipase 
Cγ, Ras/MAPK, Src kinase and Jak/Stat kinase pathways. 
Aberrant synthesis of PDGF, over-expression of PDGFR 
and concomitant autocrine growth stimulates neoplastic 
conversion of PDGFR-positive cells (Heldin and Westermark 
1999). PDGFR signaling has also been reported to stimulate 
angiogenesis and recruit pericytes which stabilize the 
tumor vasculature (Bergers et al 2003; Ostman 2004; Yokoi 
et al 2005). PDGFR signaling in the tumor raises stromal 
interstitial ﬂ  uid pressure, inhibiting effective transvascular 
transport of chemotherapeutic agents into the tumor (Pietras 
et al 2002; Yokoi et al 2005). PDGFRs and its ligand are 
overexpressed in various solid tumors including glioblastoma, 
sarcoma, breast, colorectal carcinoma and pancreatic 
cancer (Ebert et al 1995; Hwang et al 2003). Ebert et al 
demonstrated that pancreatic tumor samples exhibited a 
signiﬁ  cant increase in PDGFR-α and PDGFR-β mRNA levels 
compared with samples of normal pancreas (Ebert et al 1995). Biologics: Targets & Therapy 2008:2(4) 712
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Various approaches inhibiting PGFR signaling have included 
monoclonal PDGF receptor antibodies that block ligand 
binding and low molecular weight PDGFR TKIs.
Imatinib
Imatinib is a small molecule PDGFR TKI which in animal 
pancreatic cancer models was shown to have a limited effect 
on inhibiting tumor growth and prolonging survival but was 
very effective when combined with other chemotherapy 
agents like gemcitabine (Hwang et al 2003; Yokoi et al 
2005). Imatinib is thought to lower PDGFR mediated tumor 
interstitial hypertension, promoting transvascular transport 
of concurrent chemotherapeutic agents, although it lacks any 
signiﬁ  cant anti-tumor effect of its own (Pietras et al 2002). 
Imatinib was evaluated in advanced pancreatic cancer in a 
small clinical trial (Chen et al 2006). Twenty Six patients 
were randomly treated with either gemcitabine or single 
agent imatinib. Primary end point was time to progression. 
No signiﬁ  cant difference in median time to progression and 
median survival time was observed. Another phase II trial 
showed similar lack of efﬁ  cacy of single agent imatinib in 
advanced pancreatic cancer (Gharibo 2005). A phase I/II 
study using the imatinib and gemcitabine combination 
for advanced pancreatic cancer was recently reported 
(McGartland et al 2006). This study has enrolled 17 patients 
so far with about 50% patients experiencing disease control 
(partial response or stable disease). Most common toxicities 
were neutropenia, ﬂ  uid retention and fatigue. Dose escalation 
and further accrual continues.
Sorafenib (BAY43-9006)
Sorafenib is an oral, potent, dual action Raf protein kinase 
and VEGFR inhibitor with activity against PDGFR and 
c-Kit as well. The Ras oncogene is mutated in about 90% of 
pancreatic cancers, leading to constitutive activation of the 
Ras-Raf-MAPK signal transduction pathway. In preclinical 
studies sorafenib was shown to inhibit tumor angiogenesis 
and cell proliferation with broad-spectrum antitumor activity 
in colon, breast, and non-small-cell lung cancer xenograft 
models (Wilhelm et al 2004). Due to their compatibility in 
preclinical models and non-overlapping clinical toxicities, 
sorafenib was studied in advanced pancreatic cancer in 
combination with gemcitabine. A phase I study examined the 
combination in patients with advanced solid tumors, with an 
expanded cohort of patients with advanced pancreatic cancer 
(Siu et al 2006). This study enrolled 42 patients overall, 
with 23 patients in the extended pancreatic cancer cohort. 
Antitumor activity was observed in both groups, with 2 partial 
responses in ovarian cancer and 13 patients (56.5%) in the 
pancreatic cohort achieving disease stabilization. Sorafenib 
and gemcitabine combination was well tolerated. Based on 
these results a multi-centre phase II trial of sorafenib and 
gemcitabine in advanced pancreatic cancer was conducted, 
the results of which were recently reported (Wallace et al 
2007). Primary end-point was tumor response. No objective 
responses were observed in the ﬁ  rst 17 patients enrolled 
on the study. The study closed to accrual as it did not meet 
primary end point.
Cytoplasmic kinases Src
Src kinases are a family of non-receptor protein tyrosine 
kinases, playing critical roles in cell division regulation, 
motility, adhesion, angiogenesis and survival (Summy 
and Gallick 2003). Src kinases are controlled by tyrosine 
kinase receptors (EGFR, PDGFR, ﬁ  broblast growth factor 
receptors), integrin receptors, G-protein coupled receptors, 
cytokine receptors, and steroid hormone receptors (Thomas 
and Brugge 1997). All Src family kinases contain a tyrosine 
kinase domain. On activation, Src signals to a variety of 
downstream effectors including Stat transcription factors. 
Constitutively activated variants of Src family kinases are 
capable of inducing malignant transformation. C-Src is 
frequently overexpressed and/or aberrantly activated in a 
variety of epithelial and non-epithelial cancers including 
colorectal, breast cancers, melanomas, ovarian cancer, lung 
cancer and pancreatic cancer. C-Src over-expression and 
elevated c-Src kinase activity was observed in pancreatic 
carcinoma cell lines. Src family kinases inhibitors are thus 
attractive options for future anti-cancer therapeutics.
AZD0530
AZD0530 is the earliest Src kinase TKI to undergo 
clinical testing in pancreatic cancer. AZD0530 has low 
anti-proliferative activity but inhibits tumor cell adhesion, 
migration and invasion. A clinical phase I/II trial combing 
AZD0530 with gemcitabine in advanced pancreatic cancer 
is currently being conducted.
Dasatinib (BMS-354825)
Dasatinib is an oral dual BCR/ABL and Src family tyrosine 
kinases inhibitor currently being tested in phase I settings in 
advanced pancreatic cancer patients.
Future directions
Tyrosine kinase inhibitors have presented a new lead in devel-
opment of targeted therapies for treating pancreatic cancer. Biologics: Targets & Therapy 2008:2(4) 713
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Even though preclinical evidence and phase I/II trials for 
activity of TKIs in pancreatic cancer have been encouraging, 
phase III clinical trials involving larger number of 
patients have been disappointing. Current challenges 
include improving patient selection, identifying effective 
combinations of various classes of agents, improving the 
predictive value of current preclinical models and better 
study designs (Mendelsohn and Baselga 2003).
1)  Patient selection: The clinical activity of various agents so 
far has been observed in an unselected patient population. 
The heterogeneous nature of molecular abnormalities in 
pancreatic cancer would suggest that a targeted agent 
would be effective in only a relatively small subset of 
patients. The successful development of trastuzumab and 
imatinib in breast and sarcoma has been dependent on the 
ability to select patients with Her-2-neu overexpression 
and c-kit mutations. Therefore, it will be critical in the 
future trials to identify predictors of response to TKI 
and incorporate those predictors in patient selection for 
clinical trials.
2)  The results of clinical trials in patients with stage IV 
pancreatic cancer indicate that a substantial number of 
patients (approximately 30%) live less than 8 weeks. 
The likelihood that a therapeutic intervention will 
have a major impact within this short period of time is 
unlikely. Therefore, future consideration should be given 
to developing new agents in earlier stage disease or to 
applying more strict eligibility criteria for clinical trials in 
stage IV disease. Such criteria could include patients with 
better performance status, or patients with less baseline 
symptoms. The role of CA19-9 as a prognostic marker has 
been well established and could also be incorporated into 
the eligibility criteria of future trial (Hess et al 2008).
3)  Drug combinations: Pancreatic cancer is dependent on 
multiple dysregulated signalling pathways. Therapeutic 
blockade of any single pathway may be overcome by 
activation of alternative receptors or pathways. Therefore, 
combining targeted agents is the next rational step in the 
clinical development of TKI. Unfortunately the rationale 
for combination therapy in the era of targeted agents is 
still largely based on empiricism and non overlapping 
toxicities. Given the large number of targets and 
available inhibitors, there is a need to develop a better 
understanding of the biology to support the selection of 
agents to be evaluated in combination therapy.
4) Preclinical models: Our knowledge about molecular 
abnormalities of pancreatic cancer is limited by the 
availability of preclinical models. Although many drug 
combinations have demonstrated additive and synergistic 
effects in xenograft models, few have shown signiﬁ  cant 
clinical efﬁ  cacy. There is a need for new preclinical 
models that would better predict the clinical activity of 
new agents.
5)  Study design: With the large number of negative phase III 
trials, re-evaluation of the clinical trial paradigm has 
become necessary. Deﬁ  nitions of trial end-points used 
in current pilot phase II studies may need to be revisited 
(Mendelsohn and Baselga 2003). Possibly progression 
free survival or lack of change in tumor size may be 
more meaningful surrogates for survival than objective 
response. Randomized phase II studies or designs with 
multiple experimental arms may be necessary to choose 
the most effective and least toxic regimens for further 
testing in phase III trials.
Conclusion
The clinical development of tyrosines kinase inhibitors in 
pancreatic cancer is evolving rapidly as our understanding of 
tumor cell and receptor biology increases and the results of 
more clinical trials become available. Currently erlotinib is the 
sole tyrosine kinase inhibitor approved for use in pancreatic 
cancer. There is a need to better understand pancreatic tumor 
biology and molecular characterizations, improve patient 
selection and investigate appropriate combinations of targeted 
and chemotherapeutic agents to optimize treatment options.
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